search
Back to results

Testing of INSTI™ HIV-1 Antibody Test Kit in Volunteer Subjects at Risk for HIV Infection

Primary Purpose

HIV Infections

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Behavioral counseling
HIV-1 Antibody Test Kit
Sponsored by
bioLytical Laboratories
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for HIV Infections focused on measuring HIV 1, AIDS, Assay, Rapid Test, HIV-1, HIV Seronegativity

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Unknown HIV status who are undergoing voluntary testing for HIV infection in a POC clinic setting or known HIV seropositive subjects willing to be re-tested.
  • Ability to give proper informed consent, or have legal parent or guardian provide consent.
  • Willingness to participate in a POC standard of care HIV counseling and testing program and receive POC standard of care test results
  • Willingness to provide the necessary volume of whole blood collected through venous blood draw and finger stick (approximately 10 ml)

Exclusion Criteria:

  • Subject self-report of history of multiple myeloma
  • Subject self-report of history of long-term anti-retroviral therapy with known low or non-existent antibody titre (sero-inversion)

Sites / Locations

  • LA County STD Program
  • Michael Sumero, MD
  • UCSD Antiviral Research Center
  • Denver Public Health
  • Midland Medical
  • University of Maryland, Baltimore School of Medicine
  • Department of Epidemiology, Johns Hopkins School of Public Health
  • Crossroads Clinic
  • National Development and Research Institute
  • New York Academy of Medicine
  • Mazzoni Center
  • AIDS/HIV Services Group
  • Richmond AIDS Consortium
  • Cross Over Ministry

Outcomes

Primary Outcome Measures

INSTI™ performed with finger-stick whole blood, venous whole blood, and plasma demonstrates at least 98.0% sensitivity and specificity compared to an FDA-approved HIV testing algorithm

Secondary Outcome Measures

The percentage of INSTI™ results that agree between finger-stick whole blood, venous whole blood, and plasma.

Full Information

First Posted
August 8, 2007
Last Updated
January 26, 2021
Sponsor
bioLytical Laboratories
search

1. Study Identification

Unique Protocol Identification Number
NCT00514605
Brief Title
Testing of INSTI™ HIV-1 Antibody Test Kit in Volunteer Subjects at Risk for HIV Infection
Official Title
A Study to Evaluate the Point-of-Care Use and Laboratory Investigational Testing of INSTI™ HIV-1 Antibody Test Kit in Volunteer Subjects at Risk for HIV Infection
Study Type
Interventional

2. Study Status

Record Verification Date
January 2021
Overall Recruitment Status
Completed
Study Start Date
July 2007 (undefined)
Primary Completion Date
November 20, 2007 (Actual)
Study Completion Date
November 20, 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
bioLytical Laboratories

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Each year up to 22 million persons in the US are tested for HIV. Currently available "rapid" tests do not provide test results for at least 30 minutes from the collection of serum and plasma from the subject. Providing accurate test results in less than a minute would make it easier to make timely decisions about treatment and counselling. This study will compare results of an experimental rapid test to existing standards to determine if the test can reliably and accurately diagnose HIV in less than one minute.
Detailed Description
The primary objective is to determine if INSTI™ performed with finger-stick whole blood, venous whole blood, and plasma demonstrates at least 98.0% sensitivity and specificity compared to an FDA-approved HIV testing algorithm. The study will have two parts. The first part of the study will be conducted in institutions where HIV testing is routinely performed and where HIV counseling is offered [i.e. point of care (POC) centers]. The second part of the study will be conducted in a central laboratory that routinely conducts laboratory-based HIV testing using an FDA-licensed HIV-1 ELISA and Western blot test. Geographically diverse POCs will be selected in the USA. Approximately 15-20 POCs are planned. Approximately 2,500 subjects will participate in the study including 1,500 subjects with unknown HIV status and 1,000 seropositive subjects. Across these POC sites, voluntary testing of 1500 subjects with unknown HIV status is planned with at least 500 of these subjects being high risk. Samples will be obtained from consenting subjects in the voluntary testing population including high-risk and known HIV 1 seropositive individuals. Each subject is to receive an INSTI™ on finger-stick blood and parallel HIV testing of EDTA-treated venous whole blood and plasma samples will be conducted at a central laboratory. The results of INSTI™ will not be given to the subject. The subject will be given the results of the POC HIV test only, per their standard of care procedures. Subsequent subject care decisions will NOT be based on the results of INSTI™.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections
Keywords
HIV 1, AIDS, Assay, Rapid Test, HIV-1, HIV Seronegativity

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 2, Phase 3
Interventional Study Model
Single Group Assignment
Masking
Single
Allocation
Non-Randomized
Enrollment
2500 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Other
Intervention Name(s)
Behavioral counseling
Intervention Description
Standard-of-Care counseling at the Point-of-Care.
Intervention Type
Device
Intervention Name(s)
HIV-1 Antibody Test Kit
Other Intervention Name(s)
INSTI™ HIV-1 Antibody Test Kit
Intervention Description
Assay to detect HIV antibodies
Primary Outcome Measure Information:
Title
INSTI™ performed with finger-stick whole blood, venous whole blood, and plasma demonstrates at least 98.0% sensitivity and specificity compared to an FDA-approved HIV testing algorithm
Time Frame
<1 week
Secondary Outcome Measure Information:
Title
The percentage of INSTI™ results that agree between finger-stick whole blood, venous whole blood, and plasma.
Time Frame
< 1 week

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Unknown HIV status who are undergoing voluntary testing for HIV infection in a POC clinic setting or known HIV seropositive subjects willing to be re-tested. Ability to give proper informed consent, or have legal parent or guardian provide consent. Willingness to participate in a POC standard of care HIV counseling and testing program and receive POC standard of care test results Willingness to provide the necessary volume of whole blood collected through venous blood draw and finger stick (approximately 10 ml) Exclusion Criteria: Subject self-report of history of multiple myeloma Subject self-report of history of long-term anti-retroviral therapy with known low or non-existent antibody titre (sero-inversion)
Facility Information:
Facility Name
LA County STD Program
City
Los Angeles
State/Province
California
ZIP/Postal Code
90007
Country
United States
Facility Name
Michael Sumero, MD
City
Palm Springs
State/Province
California
ZIP/Postal Code
92262
Country
United States
Facility Name
UCSD Antiviral Research Center
City
San Diego
State/Province
California
ZIP/Postal Code
92103
Country
United States
Facility Name
Denver Public Health
City
Denver
State/Province
Colorado
ZIP/Postal Code
80204
Country
United States
Facility Name
Midland Medical
City
Fort Lauderdale
State/Province
Florida
ZIP/Postal Code
33306
Country
United States
Facility Name
University of Maryland, Baltimore School of Medicine
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21201
Country
United States
Facility Name
Department of Epidemiology, Johns Hopkins School of Public Health
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21205
Country
United States
Facility Name
Crossroads Clinic
City
Jackson
State/Province
Mississippi
ZIP/Postal Code
39216
Country
United States
Facility Name
National Development and Research Institute
City
New York
State/Province
New York
ZIP/Postal Code
10010
Country
United States
Facility Name
New York Academy of Medicine
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Facility Name
Mazzoni Center
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Facility Name
AIDS/HIV Services Group
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22902
Country
United States
Facility Name
Richmond AIDS Consortium
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23219
Country
United States
Facility Name
Cross Over Ministry
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23224
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Testing of INSTI™ HIV-1 Antibody Test Kit in Volunteer Subjects at Risk for HIV Infection

We'll reach out to this number within 24 hrs